Quick Answer
Sagimet Biosciences Inc. reported Cash And Cash Equivalents At Carrying Value of $35.02 million for the year ending 2025.
- Sagimet Biosciences Inc. showed a decrease of -53.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Sagimet Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $18.51 million | Q3 2023: $101.84 million | Q1 2024: $176.78 million | Q2 2024: $95.96 million | Q3 2024: $77.01 million | Q1 2025: $64.72 million | Q2 2025: $42.33 million | Q3 2025: $32.50 million.
- Over the full 4 years of available data (2022 to 2025), Sagimet Biosciences Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 22,065.2%.
- Historical annual values: Fiscal year 2025: $35.02 million | Fiscal year 2024: $75.84 million | Fiscal year 2023: $75.14 million | Fiscal year 2022: $158.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: